Usdan leaves Syncors center division
The president and CEO of Syncor International's Comprehensive Medical Imaging center business has left the company after only five weeks on the job, the Woodland Hills, CA, firm reported last month. James Usdan resigned from CMI effective July 10, just
The president and CEO of Syncor International's Comprehensive Medical Imaging center business has left the company after only five weeks on the job, the Woodland Hills, CA, firm reported last month. James Usdan resigned from CMI effective July 10, just over a month after he was hired to lead the division (SCAN 5/13/98). Syncor declined to state why Usdan left the company.
Syncor president and CEO Robert Funari will take over Usdan's duties on an interim basis as head of CMI until a replacement is hired. CMI was formed earlier this year to spearhead Syncor's foray into the imaging center market through the acquisitions of National Diagnostic Services and TME (SCAN 2/4/98).
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
